Anti-CD73 antibodies and uses thereof

An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, and HCDR3, a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of:

• a. SEQ ID NOs:89, 90, 91, 149, 150 and 151, respectively, or SEQ ID NOs:209, 210, 211, 269, 270 and 271, respectively;
• b. SEQ ID NOs:41, 42, 43, 101, 102 and 103, respectively, or SEQ ID NOs:161, 162, 163, 221, 222 and 223, respectively;
• c. SEQ ID NOs:44, 45, 46, 104, 105 and 106, respectively, or SEQ ID NOs:164, 165, 166, 224, 225 and 226, respectively;
• d. SEQ ID NOs:47, 48, 49, 107, 108 and 109, respectively, or SEQ ID NOs:167, 168, 169, 227, 228 and 229, respectively;
• e. SEQ ID NOs:50, 51, 52, 110, 111 and 112, respectively, or SEQ ID NOs:170, 171, 172, 230, 231 and 232, respectively;
• f. SEQ ID NOs:53, 54, 55, 113, 114 and 115, respectively, or SEQ ID NOs:173, 174, 175, 233, 234 and 235, respectively;
• g. SEQ ID NOs:56, 57, 58, 116, 117 and 118, respectively, or SEQ ID NOs:176, 177, 178, 236, 237 and 238, respectively;
• h. SEQ ID NOs:59, 60, 61, 119, 120 and 121, respectively, or SEQ ID NOs:179, 180, 181, 239, 240 and 241, respectively;
• i. SEQ ID NOs:62, 63, 64, 122, 123 and 124, respectively, or SEQ ID NOs:182, 183, 184, 242, 243 and 244, respectively;
• j. SEQ ID NOs:65, 66, 67, 125, 126 and 127, respectively, or SEQ ID NOs:185, 186, 187, 245, 246 and 247, respectively;
• k. SEQ ID NOs:68, 69, 70, 128, 129 and 130, respectively, or SEQ ID NOs:188, 189, 190, 248, 249 and 250, respectively;
• l. SEQ ID NOs:71, 72, 73, 131, 132 and 133, respectively, or SEQ ID NOs:191, 192, 193, 251, 252 and 253, respectively;
• m. SEQ ID NOs:74, 75, 76, 134, 135 and 136, respectively, or SEQ ID NOs:194, 195, 196, 254, 255 and 256, respectively;
• n. SEQ ID NOs:77, 78, 79, 137, 138 and 139, respectively, or SEQ ID NOs:197, 198, 199, 257, 258 and 259, respectively;
• o. SEQ ID NOs:80, 81, 82, 140, 141 and 142, respectively, or SEQ ID NOs:200, 201, 202, 260, 261 and 262, respectively;
• p. SEQ ID NOs:83, 84, 85, 143, 144 and 145, respectively, or SEQ ID NOs:203, 204, 205, 263, 264 and 265, respectively;
• q. SEQ ID NOs:86, 87, 88, 146, 147 and 148, respectively, or SEQ ID NOs:206, 207, 208, 266, 267 and 268, respectively;
• r. SEQ ID NOs:92, 93, 94, 152, 153 and 154, respectively, or SEQ ID NOs:212, 213, 214, 272, 273 and 274, respectively;
• s. SEQ ID NOs:95, 96, 97, 155, 156 and 157, respectively, or SEQ ID NOs:215, 216, 217, 275, 276 and 277, respectively;
• or
• t. SEQ ID NOs:98, 99, 100, 158, 159 and 160, respectively, or SEQ ID NOs:218, 219, 220, 278, 279 and 280, respectively;
• wherein the antibody or antigen-binding fragment thereof specifically binds to CD73.